NDAORALTABLET
Approved
Sep 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PAXIPAM (halazepam) is an oral benzodiazepine tablet approved in 1981 for anxiety disorders. It works by enhancing GABAergic neurotransmission in the central nervous system. The drug is a small molecule anxiolytic indicated for patients requiring short- to intermediate-term anxiety management.
LOE Approaching
As an established benzodiazepine approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on lifecycle extension rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PAXIPAM offers limited career upside given its LOE-approaching status and zero linked job openings. Roles available are primarily defensive, focused on protecting margin and market access against generic erosion rather than building a growth business. Career development would be better served on earlier-stage or higher-growth assets.
Brand Manager (Generic Defense)
Worked on PAXIPAM at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.